Chronic inflammation of the prostate type IV with respect to risk of prostate cancer

Background: Chronic inflammatory infiltrate (CII) might be involved in prostate cancer (PCA) and benign hyperplasia (BPH); however, its significance is controversial. Chronic inflammatory prostatitis type IV is the most common non cancer diagnosis in men undergoing biopsy because of suspected PCA. Objective: To evaluate potential associations of coexistent CII and PCA in biopsy specimens after prostate assessment. Design, setting, and participants: Between January 2007 and December 2008, 415 consecutive patients who underwent prostate biopsy were retrospectively evaluated. The investigated variables included Age (years) and PSA (ug/l); moreover, CII+, glandular atrophy (GA+), glandular hyperplasia (GH+), prostate Intraepithelial neoplasm (PIN+), atypical small acinar cell proliferation (ASAP+) and PCA positive cores (P+) were evaluated as categorical and continuous (proportion of positive cores). Outcome measurements and statistical analysis: Associations of CII+ and PCA risk were assessed by statistical methods. Results and limitations: In the patient population, a biopsy core positive for PCA was detected in 34.2% of cases and the rate of high grade PCA (HGPCA: bGS ! 8) resulted 4.82%. CII+ significantly and inversely associated with a positive biopsy core P+ (P < 0.0001; OR = 0.26) and HGPCA (P = 0.0005; OR = 0.05). Moreover, the associations indicated that patients with coexistent CII+ on needle biopsy were 74% less likely to have coexistent PCA than men without CII+ as well as 95% less likely to have HGPCA in the biopsy core than men without coexistent CII+. There were limits in our study which was single centre and included only one dedicated pathologist. Conclusions: There was an inverse association of chronic inflammation of the prostate type IV and risk of PCA; moreover, HGPCA was less likely to be detected in cancers associated with coexistent CII. In prostate microenvironment, prostate chronic inflammation may be protective; however, its role in PCA carcinogenesis remains controversial and needs further research.

Download Full-text

2065 INVERSE ASSOCIATION BETWEEN THE PRESENCE OF HISTOLOGICAL INFLAMMATION IN NEEDLE BIOPSY SPECIMENS AND THE POSITIVE BIOPSY FINDINGS FOR PROSTATE CANCER IN MEN WITH SERUM PROSTATE-SPECIFIC ANTIGEN LEVEL OF 10 - 50 NG/ML

The Journal of Urology ◽

10.1016/j.juro.2012.02.2230 ◽

2012 ◽

Vol 187 (4S) ◽

Author(s):

Tomoaki Terakawa ◽

Hideaki Miyake ◽

Iori Sakai ◽

Masato Fujisawa

Keyword(s):

Prostate Cancer ◽

Prostate Specific Antigen ◽

Needle Biopsy ◽

Specific Antigen ◽

Prostate Specific Antigen Level ◽

Inverse Association ◽

Antigen Level ◽

Serum Prostate Specific Antigen ◽

Biopsy Specimens ◽

Positive Biopsy

Download Full-text

Predictive Clinicopathologic Features and Prognostic assessment of pT0 prostate cancer: a case control study

10.21203/rs.3.rs-35182/v1 ◽

2020 ◽

Author(s):

Jiangnan Xu ◽

Chao Wang ◽

Jun Ouyang ◽

Jianglei Zhang ◽

Zekun Xu

Keyword(s):

Prostate Cancer ◽

Gleason Score ◽

Prostate Volume ◽

Specific Antigen ◽

Clinicopathological Features ◽

Control Group ◽

Prognostic Assessment ◽

Positive Biopsy ◽

Biopsy Core ◽

Biopsy Gleason Score

Abstract Background: pT0 prostate cancer is relatively rare. We wanted to share and explore the predictive clinicopathological features and prognosis of biopsy-proven pT0 prostate cancer in Chinese population.Methods: We retrospectively analyzed the clinicopathological and prognostic data of 8 patients with pT0 prostate cancer who received radical prostatectomy (RP) at our institution between 2006 and 2019. pT0 group was compared with a control group of 96 patients who underwent RP during the same period. Exclusion criteria included patients undergoing neoadjuvant hormone therapy or transurethral resection of the prostate (TURP) before the operation．Results: There were significant differences in the exposure rates of six clinicopathological features between two groups. Apart from finasteride use, the other five items were particularly frequent in the pT0 group: prostate-speciﬁc antigen (PSA) <10 ng/ml (7/8), one positive biopsy core only (7/8), biopsy Gleason score <7 (8/8), and prostate volume>40ml (7/8), length of biopsy positive for cancer≤2mm. When these five parameters were combined as predictive model, the sensitivity was 75%, the specificity was 99%. The 8 patients were followed up for an average of 67 months without biochemical recurrence or progression.Conclusions: Preoperative PSA, number of positive biopsy core, Gleason score, prostate volume, and the length of cancer can help predict pT0 stage of prostate cancer. Patients with pT0 stage had a relatively favorable prognosis.

Download Full-text

Inverse Association Between Histologic Inflammation in Needle Biopsy Specimens and Prostate Cancer in Men With Serum PSA of 10-50 ng/mL

Urology ◽

10.1016/j.urology.2008.07.028 ◽

2008 ◽

Vol 72 (6) ◽

pp. 1194-1197 ◽

Cited By ~ 25

Author(s):

Tomoaki Terakawa ◽

Hideaki Miyake ◽

Naoki Kanomata ◽

Masafumi Kumano ◽

Atsushi Takenaka ◽

...

Keyword(s):

Prostate Cancer ◽

Needle Biopsy ◽

Inverse Association ◽

Biopsy Specimens

Download Full-text

Application of bone scans for prostate cancer staging: Which guideline shows better result?

Canadian Urological Association Journal ◽

10.5489/cuaj.2054 ◽

2014 ◽

Vol 8 (7-8) ◽

pp. 515 ◽

Cited By ~ 2

Author(s):

Ari Chong ◽

Insang Hwang ◽

Jung-min Ha ◽

Seong Hyeon Yu ◽

Eu Chang Hwang ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastasis ◽

Bone Metastases ◽

Bone Scan ◽

Clinical Staging ◽

Receiver Operating Curve ◽

Positive Biopsy ◽

Biopsy Core ◽

Significant Difference ◽

Positive Core

Introduction: We evaluated the accuracy of current guidelines by analyzing bone scan results and clinical parameters of patients with prostate cancer to determine the optimal guideline for predicting bone metastasis.Methods: We retrospectively analyzed patients who were diagnosed with prostate cancer and who underwent a bone scan. Bone metastasis was confirmed by bone scan results with clinical and radiological follow-up. Serum prostate-specific antigen, Gleason score, percent of positive biopsy core, clinical staging and bone scan results were analyzed. We analyzed diagnostic performance in predicting bone metastasis of the guidelines of the European Association of Urology (EAU), American Urological Association (AUA), and the National Comprehensive Cancer Network (NCCN) guidelines as well as Briganti’s classification and regression tree (CART). We also compared the percent of positive biopsy core between patients with and without bone metastases.Results: A total 167 of 806 patients had bone metastases. Receiver operating curve analysis revealed that the AUA and EAU guidelines were better for detecting bone metastases than were Briganti’s CART and NCCN. No significant difference was observed between AUA and EAU guidelines. Patients with bone metastases had a higher percent positive core than did patients without metastasis (the cut-off value >55.6).Conclusion: The EAU and AUA guidelines showed better results than did Briganti’s CART and NCCN for predicting bone metastasis in the enrolled patients. A bone scan is strongly recommended for patients who have a higher percent positive core and who meet the EAU and AUA guidelines.

Download Full-text